KLRK1 Antibody - #DF4816

Fig. 1 CircARAP2 is upregulated in sMICA-induced NK cell desensitization. A The workflow of profiling circRNAs associated with sMICA-induced NK cell desensitization. B Flow cytometry and RT-qPCR analysis of NKG2D expression on NK92 and human primary activated NK cells treated with rsMICA for 24 h. n = 3 for NK92 cells, n = 8 for activated NK cells; Unpaired two-tailed t-test for RT-qPCR analysis, paired two-tailed t-test for flow cytometry analysis. C Left panel, Representative IF image of NKG2D and RAB5 on NK92 (Scale bar, 20 μm) and human primary activated NK (Scale bar, 10 μm) cells treated with rsMICA; Right panel, Quantification of Pearson coefficient of colocalization in pairs NKG2D/RAB5 on NK92 and human primary activated NK cells following rsMICA treatment (Repeats = 3, unpaired two-tailed t-test). D Immunoblot of NKG2D in both NK92 and human primary activated NK cells treated with rsMICA. Data represent three independent experiments, unpaired two-tailed t-test. E The calcein-AM release assay was used to assess the cytotoxicity of NK92 and human primary activated NK cells following rsMICA treatment. Data are presented of three independent experiments, two-way ANOVA. F Flow cytometry was used to assess the IFN-γ, Granzyme B and CD107a expression in both NK92 and human primary activated NK cells treated with rsMICA. Data are presented of three independent experiments, paired two-tailed t-test. G Flow cytometry was used to assess the expression of inhibitory receptors TIGIT and CD96 in NK92 and human primary activated NK cells with rsMICA treatment. Data are presented of three independent experiments, paired two-tailed t-test. H Volcano plot showing differentially expressed circRNAs in NK92 samples with or without rsMICA treatment (Left panel). KEGG analysis showing enrichment of differentially expressed circRNAs in the endocytosis pathway (Middle panel). Heatmap showing changes in expression levels of circRNAs enriched in the endocytosis pathway (Right panel). I Expression of circARAP2 and linear ARAP2 in both NK92 (n = 3) and primary activated NK cells (n = 10) after treatment with rsMICA. Unpaired two-tailed t-test was used for the comparison of two groups. (ns no significance, *P